Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia.

ABSTRACT: Response to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML) is monitored by quantification of BCR::ABL1 transcript levels. Milestones for assessing optimal treatment response have been defined in adult CML patients and are applied to children and adolescents although it is questionable whether transferability to pediatric patients is appropriate regarding genetic and clinical differences. Therefore, we analyzed the molecular response kinetics to TKI therapy in 129 pediatric CML patients and investigated whether response assessment based on continuous references can support an early individual therapy adjustment. We applied a moving quantiles approach to establish a high-resolution response target curve and contrasted the median responses in all patie

SUBMITTER: Volz C 

PROVIDER: S-EPMC10598002 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature